Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS-1502 + Srulizumab ± chemotherapy in HER2-expressing advanced gastric cancer
ChiCTR2500099447Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of caxmotabart entudotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Dose-limiting toxicity (DLT) occurrence in safety introduction phase and Objective response rate (ORR). Started Sep 2022; status: completed.
02
Drugs
caxmotabart entudotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500099447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099447.